High dose oral ganciclovir treatment for cytomegalovirus retinitis
Jacob Lalezari(Quest Clinical Research (United States)), Charles A. Robinson(Center for Global Development), Panos Georgiou(Roche (United Kingdom)), William Buhles(Unknown), Jack Bissett(Infectious Disease Consultants), M Giordano(Cornell University), W. D. Hardy(University of California, Los Angeles), Dorothy N. Friedberg(Columbia University Irving Medical Center), Larry D. Hubbard(University of Minnesota), Mary Jean Stempien(Palo Alto Institute), Donald Jung(Anshan Hospital), William Drew(University of California San Francisco Medical Center)
Cited by 45
Related Papers
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
Sjögren's syndrome. Proposed criteria for classification
|Arthritis & Rheumatism|1986|685
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
|The Lancet|1997|501
Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant
|New England Journal of Medicine|1999|485
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
|New England Journal of Medicine|2002|394